Brain and nerves
268 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| 1 mg QD to 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 120 milligrams of ENERGI-F705 Tablets for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 3 mg QD to 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 30mg PRAX-628 for epilepsy, generalized | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 30mg PRAX-628 for seizures | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 60 milligrams of ENERGI-F705 Tablets for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 7 mg QD to 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aav-gad for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AAV9-Follistatin gene therapy for sarcopenia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AAV9-Follistatin gene therapy + VEGF Plasmid for sarcopenia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AB-1005 for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ACP-204 for hallucinations | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Activa PC+S Neurostimulator for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active tDCS with Sternberg task for neuralgia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Active, self-directed electrical stimulation of the median nerve for tics | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acupuncture for agnosia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Adaptive (Closed Loop) DBS + Intermittent Open Loop DBS + Open Loop DBS for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Adaptive (Closed Loop) DBS + Open Loop DBS for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Adaptive DBS for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Adaptive DBS (Activa PC+S Neurostimulator) + Continuous DBS (Activa PC+S Neurostimulator) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| adaptive DBS (aDBS) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| adaptive DBS delivered through AlphaDBS IPG System for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| adaptive deep brain stimulation + conventional deep brain stimulation for dyskinesias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| adaptive deep brain stimulation + conventional deep brain stimulation for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| aDBS-Extended (Medtronic Percept™) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Agilik for cerebral palsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Agilik for spinal dysraphism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Agilik + standard care for cerebral palsy | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Allay Lamp for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ambroxol for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Apitegromab for muscular atrophy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Apitegromab for spinal muscular atrophies of childhood | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| apomorphine infusion for dyskinesias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| apomorphine infusion for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ARC-BSI Lumbar system for paraplegia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aticaprant for anhedonia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| ATLAS 2030 exoskeleton for cerebral palsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| autologous dopaminergic cell implantation for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autologous midbrain dopamine neurons for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Baclofen for psychomotor agitation | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bexicaserin for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bexicaserin for seizures | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BIIB122 for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BIIB122 225 mg for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood sampling for microRNA testing for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bocunebart for migraine disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BR005-036C for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BrainGate Neural Interface System for aphasia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BrainGate Neural Interface System for aphasia, broca | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BrainGate Neural Interface System for dysarthria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BrainGate Neural Interface System for locked-in syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brivaracetam for epilepsy, absence | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Buprenorphine hydrochloride for agnosia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for drug resistant epilepsy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Cannabidiol for epilepsy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Cannabidiol for epilepsy, absence | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol for lennox gastaut syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Cannabidiol for seizures | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Cannabidiol for spasms, infantile | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| CapeOX + bevacizumab + PD-1 Inhibitors + SBRT for spinocerebellar degenerations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Capivasertib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carboplatin + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Carboplatin + ELRAGLUSIB + Paclitaxel for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cenobamate (syrup) for 2 to < 18 year olds + Cenobamate (tablet) for 12 to < 18 year olds for epilepsies, partial | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Chronic speech BCI for locked-in syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Chronic speech BCI for speech disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Closed-loop stimulation + GPi alone + STN + GPi + STN alone for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CMP-002 for nervous system diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 non-invasive device for corticobasal degeneration | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 non-invasive device for dystonia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 non-invasive device for multiple system atrophy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 non-invasive device for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CVN424 150 mg for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| CVN424 75 mg for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphaticovenous Anastomosis(DLVA) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Depression Cognitive Training + tDCS (active stimulation) for neurobehavioral manifestations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Depression Cognitive Training + tDCS (sham stimulation) for neurobehavioral manifestations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device: Directional Deep Brain Stimulation for epilepsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Dexmedetomidine hydrochloride for dysautonomia, familial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet + Exercise + Meditation for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Divalproex sodium for mania | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab for down syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Doxorubicin hydrochloride + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DSP-1083 implantation for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elismetrep for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elraglusib for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ELRAGLUSIB + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| endoscopic repair of myelomeningocele before 26 SA for meningomyelocele | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Epidural Electrical Stimulation (EES) using an implanted paddle lead and pulse generator combined with a 12-month intensive rehabilitation program. for paraplegia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Epidural spinal cord stimulation for paraplegia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Epidural spinal cord stimulation for primary dysautonomias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Epidural Spinal Cord Stimulation System for primary dysautonomias | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Epidural Spinal Stimulation (ESS) + Upper extremity rehabilitation for quadriplegia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eptinezumab for migraine disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab for epilepsy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 22 |
| Erenumab + calcitonin gene-related peptide for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab 70 mg + GALCANEZUMAB + ATOGEPANT + EPTINEZUMAB for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab matching placebo + ERENUMAB for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab-Aooe 140 MG/ML [Aimovig] for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Escitalopram oxalate for aphasia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Escitalopram oxalate for lethargy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Essential Amino Acid Supplementation for muscular atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ETX101 for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Ex-cipn for peripheral nervous system diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exenatide for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Exogenous ketone ester for drug resistant epilepsy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exogenous ketone ester for status epilepticus | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fetoscopic repair of spina bifida for arnold-chiari malformation | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fetoscopic repair of spina bifida for hydrocephalus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fetoscopic repair of spina bifida for meningomyelocele | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fetoscopic repair of spina bifida for spina bifida cystica | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fetoscopy for arnold-chiari malformation | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Fetoscopy for meningomyelocele | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Fetoscopy for spina bifida cystica | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fetoscopy for spinal dysraphism | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| FLORTAUCIPIR F-18 for neurodegenerative diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FLUOROETHOXYBENZOVESAMICOL F-18 for down syndrome | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fluoxetine for down syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Focused Transcranial Ultrasound for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FULVESTRANT + Tersolisib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Galcanezumab for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Galcanezumab + erenumab + fremanezumab for migraine disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GALCANEZUMAB + Ubrogepant for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GC101 for muscular atrophy, spinal | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Glyceryl Trinitrate Only Product in Oromucosal Dose Form for autonomic dysreflexia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green light for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-Intensity Aerobic Exercise (AE) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Iluzanebart for leukoencephalopathies | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IM ketamine in dose finding and then continuation for phantom limb | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Imifoplatin for peripheral nervous system diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) for lethargy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for lethargy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Internet-Based Intervention + Quality-of-Life Assessment + Questionnaire Administration for trismus | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ION337 for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IPILIMUMAB + SINTILIMAB + Cetuximab + DABRAFENIB for spinocerebellar degenerations | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Irinotecan + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ivermectin for olfaction disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JZP926 capsule for myoclonic epilepsy, juvenile | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketoprofen for agnosia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ASPARAGINASE ERWINIA CHRYSANTHEMI + ASPARAGINASE + Mitoxantrone Hydrochloride for down syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Laboratory Biomarker Analysis + CYTARABINE + ETOPOSIDE + THIOGUANINE + Daunorubicin Hydrochloride for down syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Leia Sensory Prosthesis for peripheral nervous system diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| lentiviral gene therapy for drug resistant epilepsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Leucovorin for language disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Levetiracetam for seizures | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Levoleucovorin calcium for language disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Lidocaine for migraine disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lifus for dystonia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lifus for epilepsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lifus for essential tremor | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lifus for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lithium for mania | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lithium sulphate prolonged-release 660 mg for tremor | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lixisenatide for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lomustine + ELRAGLUSIB for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3884961 + Sirolimus + Methylprednisolone for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active) for lethargy | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Metformin for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Methylcobalamin for peripheral nervous system diseases | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MF-300 for sarcopenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Minimally invasive fetoscopic repair of MMC for meningomyelocele | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Minimally invasive fetoscopic repair of MMC for spinal dysraphism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MiraBurst for dysgeusia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ML-007C-MA for brain diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Modified deep cervical Lymphatic-Venous Anastomosis for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MRI + Psilocybin + Risperidone for anhedonia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| N1 Implant + R1 Robot for dysarthria | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| N1 Implant + R1 Robot for quadriplegia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Neridronic acid for reflex sympathetic dystrophy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Neural Prosthetic System 2 (NPS2) for quadriplegia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotinamide riboside for peripheral nervous system diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NightWare for primary dysautonomias | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Non-Specific Cognitive Training + tDCS (sham stimulation) for neurobehavioral manifestations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NTLA-2001 for polyneuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| OAV101 for bulbo-spinal atrophy, x-linked | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| OAV101 for muscular atrophy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Onabotulinumtoxin-A for migraine disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Onasemnogene abeparvovec for bulbo-spinal atrophy, x-linked | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Onasemnogene abeparvovec for muscular atrophy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Onasemnogene abeparvovec for muscular atrophy, spinal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Onasemnogene abeparvovec for spinal muscular atrophies of childhood | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Opakalim for drug resistant epilepsy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Opakalim for epilepsies, partial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Opakalim for seizures | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Oxytocin for sarcopenia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Paired Vagus Nerve Stimulation for paresis | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Paxalisib for focal cortical dysplasia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PBT-434 for multiple system atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEMBROLIZUMAB + Porustobart for spinocerebellar degenerations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Percept™ PC and Percept RC with Adaptive DBS (aDBS™) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Percutaneous epidural electrical spinal stimulation for paraplegia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Percutaneous epidural electrical spinal stimulation for quadriplegia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 high dose (15 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 low dose (1 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 middle dose 1 (3 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 middle dose 2 (7 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Placebo for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Psilocybin for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Placebo + TAVAPADON + TRIMETHOBENZAMIDE HYDROCHLORIDE for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo Nasal Spray for sarcopenia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prasinezumab for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| PRT-064040 nasal spray for migraine disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for agnosia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for anhedonia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Psilocybin for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Psilocybin for neuralgia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Psilocybin for paraplegia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Psilocybin for quadriplegia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin + PIMAVANSERIN for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RAP-219 for epilepsies, partial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RAP-219 for seizures | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rapid sedation for status epilepticus | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RECLAIM System for locked-in syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relutrigine for spasms, infantile | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Risdiplam for muscular atrophy, spinal | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| ROC-101 for hereditary sensory and autonomic neuropathies | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rocuronium 1.5mg/kg/hr for muscle hypotonia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Rugonersen for angelman syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Satralizumab for myelin oligodendrocyte glycoprotein antibody-associated disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Silkworm pupa tablets for sarcopenia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SKG0201 Injection for spinal muscular atrophies of childhood | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SonoCloud-4 (SC4) device for neuroinflammatory diseases | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads) for spinal muscular atrophies of childhood | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®) with the Magnus Neuromodulation System for memory disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Stent Implantation for pseudotumor cerebri | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Step count goal for chronobiology disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| stimulation device for akinetic mutism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| stimulation device for persistent vegetative state | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| STK-001 - Single Ascending Doses for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| SUN-627 for neuroinflammatory diseases | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Suzetrigine for agnosia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Synsepalum dulcificum fruit for dysgeusia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Targeted Epidural Spinal Stimulation for autonomic dysreflexia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tavapadon for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Tersolisib for hereditary sensory and autonomic neuropathies | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TEV-56286 for multiple system atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| The LFP Beta aDBS System for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| the Terumo Hydropearl® microspheres device for agnosia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tominersen for chorea | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Total knee replacement for muscular atrophy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcranial Direct Current Stimulation for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcranial focused ultrasound stimulation for essential tremor | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcutaneous electrical spinal stimulation for paraplegia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcutaneous electrical spinal stimulation for quadriplegia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ubrogepant + ERENUMAB for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Unicompartmental knee replacement for muscular atrophy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vagus nerve stimulation; for persistent vegetative state | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valproic acid for mania | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vasopressin for agnosia | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VCA-894A for charcot-marie-tooth disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VER-01 for neuralgia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| VX-670 for myotonia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| YA-101 for multiple system atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zorevunersen for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |